drugset / Trial / NCT02608177

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

NCT02608177

RandomizedCrossoverDouble-blindTreatment

Summary

The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability. Blood glucose is measured using a continuous glucose monitoring device.

Timeline

Start
2015-11
Primary completion
2017-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Glipizide Small molecule
Subject Linagliptin Small molecule